

Applicant: Garrity et al.
Serial No.: 09/761,969
Filed: January 16, 2001
Page 5 of 16

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A kit for determining a concentration of a vitamin D component comprising:

a releasing composition including a cyclodextrin, a salicylate, and an aqueous base component selected from the group consisting of NaOH and KOH, the cyclodextrin, the salicylate, and the aqueous base component being provided in an amount effective to reduce interference from a protein or a lipid with a vitamin D component present in a sample; and

a detecting composition including a label provided in an amount to produce a detectable signal when the vitamin D component is present in the sample. ;

Bl
~~the releasing composition comprises an aqueous base component and facilitates in releasing the vitamin D component from a vitamin D component binding protein, the detecting composition facilitates in determining the concentration of the vitamin D component.~~

2. (Currently amended) A kit of claim 1, wherein the cyclodextrin, the salicylate, and the aqueous base component are provided in an amount effective to reduce interference from proteins or fatty acids with a vitamin D component present in a sample of a mammal fluid, being useful for determining the concentration of the vitamin D component present in a mammal fluid.

3. (Currently amended) A kit of claim 2 wherein the mammal fluid is selected from the group consisting of milk, whole blood, serum, and plasma and mixtures thereof.

4. (Previously presented) A kit of claim 2 wherein the mammal fluid comprises a human serum.

Applicant: Garrity et al.
Serial No.: 09/761,969
Filed: January 16, 2001
Page 6 of 16

5. (Original) A kit of claim 1 wherein the vitamin D component is selected from the group consisting of a metabolite of vitamin D2, D3, D4, D5, and D6.
6. (Original) A kit of claim 1 wherein the vitamin D component comprises a 25-OH-D.
7. (Original) A kit of claim 1 wherein the vitamin D component comprises a 1, 25-(OH)2-D.
8. (Original) A kit of claim 1 wherein the aqueous base component comprises NaOH.
9. (Original) A kit of claim 1 wherein the aqueous base component comprises KOH.
10. (Original) A kit of claim 1 wherein the releasing composition comprises about 0.1 to about 1.0 M of the aqueous base component.
11. (Currently amended) A kit of claim 1 wherein the releasing composition comprises about 0.35 to about 0.5 M of the aqueous base component, wherein the aqueous base component is NaOH.
12. (Currently amended) A kit of claim 1 wherein the releasing composition is substantially free of an organic solvent.
- 13-14. (Cancelled)
15. (Currently amended) A kit of claim 1 wherein the cyclodextrin ~~eyele-oligomer~~ component is selected from the group consisting of alpha-cyclodextrin and a beta-methylated ~~beta-randomly-methylated~~-cyclodextrin.
16. (Currently amended) A kit of claim 1 wherein the releasing composition comprises about 0.01 to about 5% of the cyclodextrin ~~eyele-oligomer~~ component.

Applicant: Garrity et al.
Serial No.: 09/761,969
Filed: January 16, 2001
Page 7 of 16

17. (Currently amended) A kit of claim 1 ~~13~~ wherein the releasing composition ~~component~~ comprises about 2% of the ~~cycle-oligomer component~~, wherein the ~~cycle-oligomer component~~ is an alpha-cyclodextrin.
18. (Currently amended) A kit of claim 1 ~~13~~ wherein the releasing composition ~~component~~ comprises about 0.05% of the ~~cycle-oligomer component~~, wherein the ~~cycle-oligomer component~~ is a ~~beta-randomly-methylated~~ beta-methylated cyclodextrin.
19. (Currently amended) A kit of claim 1 wherein the releasing composition ~~component~~ ~~further~~ comprises about 0.5 to about 5% of a metal salicylate, ~~including sodium salicylate~~.
20. (Currently amended) A kit of claim 1 wherein the releasing composition ~~component~~ further comprises about 0.01 to about 0.1% of a surfactant.
21. (Cancelled)
22. (Original) A kit of claim 1 wherein the releasing composition forms a homogeneous mixture with a mammal fluid.
23. (Currently amended) A kit of claim 1 wherein the releasing composition comprises about 0.1 to about 1.0 M of the ~~an~~ aqueous base component; about 0.01 to about 5% of the cyclodextrin ~~a cycle-oligomer component~~; and about 0.01 to about 5% of the ~~a metal~~ salicylate.
24. (Currently amended) A kit of claim 23 wherein the aqueous base component is NaOH, ~~the cycle-oligomer component is cyclodextrin~~ and the ~~metal~~ salicylate is sodium salicylate.

Applicant: Garrity et al.
Serial No.: 09/761,969
Filed: January 16, 2001
Page 8 of 16

25. (Original) A kit of claim 1 wherein the detecting composition comprises a host component and a partner component, wherein the host component binds to the partner component to form a partner/host complex, the concentration of the complex is proportional to the concentration of the vitamin D component.
26. (Original) A kit of claim 25 wherein the host component comprises an antibody, portions thereof, or mixtures thereof.
27. (Original) A kit of claim 25 wherein the host component is labeled with a chemiluminescent label, a fluorescent label or a radio-active label.
28. (Original) A kit of claim 25 wherein the host component is an antibody labeled with acridinium.
29. (Original) A kit of claim 25 wherein the partner component comprises a vitamin D component linked to a separator component, the separator component is a solid phase or an antibody.
30. (Original) A kit of claim 29 wherein the separator component comprises a magnetic particle.
31. (Original) A kit of claim 29 wherein the partner component comprises a vitamin D component linked to a magnetic particle.
32. (Original) A kit of claim 31 wherein the partner component competes with the vitamin D component to bind to the host component.
33. (Original) A kit of claim 32 wherein the host component is an antibody labeled with acridinium.

Applicant: Garrity et al.
Serial No.: 09/761,969
Filed: January 16, 2001
Page 9 of 16

34. (Original) A kit of claim 32 wherein the partner component binds to the host component through at least one intermediate binding component.
35. (Original) A kit of claim 34 wherein the intermediate component is labeled.
36. (Original) A kit of claim 34 wherein the intermediate component is labeled and the host component is not labeled.
37. (Previously presented) A kit of claim 34 wherein at least one intermediate binding component comprises a vitamin D binding-protein.
38. (Original) A kit of claim 25 wherein the partner component competes with a vitamin D component to form a complex with the host component, the partner component comprises a vitamin D component linked to a magnetic particle, the partner component binds to the host component through a vitamin D binding-protein, the host component comprises an antibody labeled with acridinium.
39. (Original) A kit of claim 38 wherein the concentration of the complex is inversely proportional to the concentration of the vitamin D component.
40. (Currently amended) A kit of claim 1 wherein the concentration of the vitamin D component is determined with a higher precision than that of an assay kit relying on an organic solvent[[,]] to release the vitamin D component from the binding-protein.
41. (Original) A kit of claim 1 wherein the releasing composition forms a homogeneous mixture with a body fluid containing the vitamin D component.
- 42-84. (Cancelled)

BI
cons

Applicant: Garrity et al.
Serial No.: 09/761,969
Filed: January 16, 2001
Page 10 of 16

85. (New) A kit of claim 1, wherein the releasing composition includes about 0.1 to about 1.0 M of NaOH or KOH, 0 to about 5% of the cyclodextrin, 0 to about 5% of salicylate and 0 to about 0.1% of a surfactant, and wherein the detecting composition includes an antibody labeled with acridinium.

Bill
CNS